Aducanumab is used in the treatment of Alzheimer’s disease. It targets amyloid-beta plaques in the brain, which are believed to contribute to the progression of the disease. By reducing these plaques, aducanumab aims to slow cognitive decline in patients with early-stage Alzheimer’s. It is administered intravenously and is intended for individuals with mild cognitive impairment or early dementia due to Alzheimer’s. The treatment is part of a disease-modifying approach rather than just managing symptoms.